PDCD1 and neoplasm: However, shTRIM32 significantly inhibited tumor growth, and the combination of shTRIM32 with anti-PD-1 therapy led to a more pronounced reduction in tumor volume and weight compared to shTRIM32 alone (Fig. 7A-C).